SLC30A10 and Alzheimer disease: SLC30A10 has consistently shown to be significantly reduced in the frontal cortex of AD patients, and in APP/PS1 transgenic mice, suggesting that its dysregulation contributes to the pathology of AD (Bosomworth et al., 2013).